The Use of Ginkgo Biloba in Clinical Care for Dementia
Introduction
Dementia, a complex and progressive neurological condition, presents significant challenges in clinical management. Among the various therapeutic options explored, Ginkgo biloba (Gb) extracts have been a subject of considerable interest. Despite ongoing debates, numerous studies have investigated the efficacy of Ginkgo biloba extracts (GbE) in treating dementia, particularly Alzheimer’s disease (AD), vascular dementia (VaD), and mixed dementia. This blog explores the potential benefits of Ginkgo biloba in dementia care, discussing the epidemiology, pathophysiology, etiology, medical treatment, and herbal interventions associated with this ancient plant.
Epidemiology of Dementia
Dementia is a global health concern affecting approximately 47 million people, with numbers expected to rise to 131 million by 2050 due to an aging population (Ponjoan et al., 2019). This increase places immense social and economic burdens on patients, caregivers, and healthcare systems, with an estimated $818 billion required annually for dementia care (Wolters et al., 2018). Dementia is primarily an impairment-related condition, heavily impacting the quality of life, independence, and mortality rates, particularly in older adults.
Pathophysiology of Dementia
Dementia encompasses a spectrum of cognitive impairments, primarily caused by hypoperfusion in critical brain regions such as the parietal and temporal lobes. The two most common forms are Alzheimer’s disease (AD), which accounts for 75% of cases, and vascular dementia (VaD), which comprises 20% (Akter et al., 2021). In AD, amyloid plaques and tau protein tangles lead to synaptic loss and neurotransmission dysfunction, contributing to cognitive decline (Kalaria, 2016). VaD, on the other hand, is associated with cerebral atrophy due to the abnormal accumulation of native proteins (Cunningham et al., 2015). Despite the variety of pathological mechanisms, neuropathological evidence remains crucial for a definitive diagnosis of dementia (Akter et al., 2021).
Aetiology of Dementia
Dementia’s etiology is multifaceted, often involving progressive neurological diseases that trigger inflammation and apoptosis in brain cells (Welcome, 2019). While some forms of dementia are irreversible, others can be managed by addressing underlying conditions such as dysbiosis, blood-brain barrier dysfunction, drug and alcohol toxicity, depression, metabolic disorders, and central nervous system infections (Rone-Adams et al., 2013). Understanding these underlying factors is essential in developing effective treatment strategies.
Conventional Medical Treatment
Pharmacological management of dementia typically involves psychoanaleptics, a class of drugs that includes antidepressants, psychostimulants, nootropics, and anti-dementia medications (Bryant et al., 2019). Centrally acting anticholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, are commonly used to manage symptoms (Bryant et al., 2019). Donepezil, for example, inhibits the N-methyl-D-aspartate (NMDA) receptor, playing a crucial role in treating dementia-related cognitive decline (Ates-Alagoz & Adejare, 2013).
Herbal Intervention: The Role of Ginkgo Biloba
Ginkgo biloba, a “living fossil” dating back 200 million years, has been traditionally used in Chinese medicine, primarily for its seeds (Singh et al., 2008). The primary active constituents of GbE are flavonoid glycosides and terpene trilactones, which are known for their neuroprotective properties (Bastianetto et al., 2000). GbE modulates phospholipase A2 (PLA2), an enzyme that protects hippocampal neurons from toxicity induced by amyloid-beta, a key component of amyloid plaques in dementia (Tomino et al., 2021). Additionally, PLA2 plays a role in neuroinflammation and oxidative stress, processes implicated in various neurological disorders, including dementia (Kumar et al., 2017). GbE also acts as an antioxidant, reducing capillary fragility and offering potential benefits in vascular dementia (Medscape, 2021).
Evaluation and Critique of the Literature
Efficacy
The majority of research suggests that higher doses of GbE (240 mg daily) may offer slight improvements in cognitive function and daily activities in patients with AD, VaD, or mixed dementias (Bohlken & Kostev, 2022). However, the efficacy of lower doses (120 mg) is less consistent (Canevelli et al., 2014). While some studies demonstrate positive outcomes with GbE, particularly when combined with other treatments, others show no significant difference compared to placebo (DeKosky et al., 2008; Schneider et al., 2005).
Safety
GbE is generally well-tolerated, with mild side effects such as headaches, sleeplessness, and gastrointestinal disturbances being the most commonly reported (Yancheva et al., 2009). Compared to conventional cholinesterase inhibitors (ChEIs), GbE appears to have a comparable effect on cognitive symptoms but with a lower risk of adverse events (Rapp et al., 2018).
Discussion and Substantiation
A comprehensive review of 12 studies, including randomized controlled trials (RCTs) and cohort studies, revealed mixed results regarding GbE’s efficacy in dementia care. Some studies suggest that GbE, alone or in combination with other therapies, may improve cognitive function and daily living activities more effectively than placebo (Ihl et al., 2012; Zhang et al., 2020). However, other studies found no significant benefit, particularly in long-term trials (DeKosky et al., 2008; Vellas et al., 2012).
Conclusion
Ginkgo biloba offers a promising alternative or adjunctive treatment for dementia, particularly for those seeking a natural approach. While GbE has shown efficacy in some studies, its benefits may be more pronounced when used in combination with other herbs or pharmaceuticals. Given the complexities of dementia and the challenges in accurate diagnosis, a bio-individualized approach to GbE formulation could enhance therapeutic outcomes. Further research is needed to refine these strategies and explore the full potential of Ginkgo biloba in dementia care.
References
Akter, R., Kaushik, D., Kumar, K., & Rahman, M. (2021). Behavioral Pathophysiology and Psychological Implications for Sleep Disorder in Dementia. In Autism Spectrum Disorder and Alzheimer’s Disease. Springer, Singapore. https://web-p-ebscohost- com.torrens.idm.oclc.org/ehost/pdfviewer/pdfviewer? vid=1&sid=0a5dc33e-4b1b-47c6-8057-da142db36b00%40redis
Ates-Alagoz, Z., & Adejare, A. (2013). NMDA Receptor Antagonists for Treatment of Depression. Pharmaceuticals (Basel, Switzerland), 6(4), 480–499. https://doi.org/ 10.3390/ph6040480
Bastianetto Stéphane, Ramassamy, C., Doré Sylvain, Christen, Y., Poirier, J., & Quirion Rémi. (2000). The ginkgo biloba extract (egb 761) protects hippocampal neurons against cell death induced by β-amyloid. European Journal of Neuroscience, 12(6), 1882–1890. https://web-p-ebscohost-com.torrens.idm.oclc.org/ehost/pdfviewer/pdfviewer? vid=1&sid=6d05763f-b0f4-47f3-b1ce-c5629d54746e%40redis
Bohlken, J., Peters, O., & Kostev, K. (2022). Association Between Ginkgo Biloba Extract Prescriptions and Dementia Incidence in Outpatients with Mild Cognitive Impairment in Germany: A Retrospective Cohort Study. Journal of Alzheimer’s Disease, 1-7. https:// content.iospress.com/download/journal-of-alzheimers-disease/jad215348?id=journal-of-alzheimers-disease%2Fjad2153488
Bryant, B. J., Knights, K. M., Darroch, S., & Rowland, A. (2019). Pharmacology for health professionals (5th ed.). Elsevier Australia. https://ebookcentral-proquest- com.torrens.idm.oclc.org/lib/think/reader.action?docID=5703985
Canevelli, M., Adali, N., Kelaiditi, E., Cantet, C., Ousset, P.-J., & Cesari, M. (2014). Effects of gingko biloba supplementation in alzheimer’s disease patients receiving cholinesterase inhibitors: data from the ictus study. Phytomedicine, 21(6), 888–892. https://doi.org/ 10.1016/j.phymed.2014.01.003
Chassagne, F., Huang, X., Lyles, J. T., & Quave, C. L. (2019). Validation of a 16th century traditional chinese medicine use of Ginkgo biloba as a topical antimicrobial. Frontiers in microbiology, 775. https://www.frontiersin.org/articles/10.3389/fmicb.2019.00775/full? _ga=2.64886444.2014487475.1555693389-1114707248.1555693389
Cunningham, E. L., McGuinness, B., Herron, B., & Passmore, A. P. (2015). Dementia. The Ulster medical journal, 84(2), 79–87. https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC4488926/
DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., Lopez, O. L., Burke, G., Carlson, M. C., Fried, L. P., Kuller, L. H., Robbins, J. A., Tracy, R. P., Woolard, N. F., Dunn, L., Snitz, B. E., Nahin, R. L., & Furberg, C. D. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. Jama, 300(19), 2253–62. https://doi.org/10.1001/jama.2008.6839
Gschwind, Y. J., Bridenbaugh, S. A., Reinhard, S., Granacher, U., Monsch, A. U., & Kressig, R. W. (2017). Ginkgo biloba special extract li 1370 improves dual-task walking in patients with mci: a randomised, double-blind, placebo-controlled exploratory study. Aging Clinical and Experimental Research, 29(4), 609–619. https://doi.org/10.1007/ s40520-016-0699-y
Ihl, R., Tribanek, M., Bachinskaya, N., & GOTADAY Study Group. (2012). Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761 in Alzheimer’s disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry, 45(02), 41-46. https://doi.org/10.1016/S1474-4422(12)70206-5
Kalaria, R. N. (2016). Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer’s disease. Acta neuropathologica, 131(5), 659-685. https://link.springer.com/content/pdf/10.1007/s00401-016-1571-z.pdf
Kumar Singh, S., E Barreto, G., Aliev, G., & Echeverria, V. (2017). Ginkgo biloba as an alternative medicine in the treatment of anxiety in dementia and other psychiatric disorders. Current drug metabolism, 18(2), 112-119. https://pubmed.ncbi.nlm.nih.gov/ 27908257/
Medscape. (2021). Ginkgo Biloba. https://reference.medscape.com/drug/eun-haeng-fossil-tree- ginkgo-biloba-344537#1010
Nacu, A., & Hoerr, R. (2016). Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761 treatment: additional results from a 24-week randomized, placebo-controlled trial. Open access journal of clinical trials, 8, 1. https:// www.proquest.com/docview/2229251397?accountid=176901
Nasab, N. M., Bahrammi, M. A., Nikpour, M. R., Rahim, F., & Naghibis, S. N. (2012). Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer’s dementia. Age (Years), 65(4.63), 65-72. https://www.jpma.org.pk/PdfDownload/3551
Rapp, M., Burkart, M., Kohlmann, T., & Bohlken, J. (2018). Similar treatment outcomes with Ginkgo biloba extract EGb 761 and donepezil in Alzheimer’s dementia in very old age: a retrospective observational study. International journal of clinical pharmacology and therapeutics, 56(3), 130. https://doi.org/10.5414/CP203103
Rone-Adams, S., Stern, D. F., Olivier, T. W., & Blodgett, M. G. (2013). Understanding dementia: Etiology, communication, and exercise intervention. Strength & Conditioning Journal, 35(4), 88-98. https://journals.lww.com/nsca-scj/Fulltext/2013/08000/ Understanding_Dementia__Etiology,_Communication,.13.aspx
Schneider, L. S., DeKosky, S. T., Farlow, M. R., Tariot, P. N., Hoerr, R., & Kieser, M. (2005). A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Current Alzheimer Research, 2(5), 541-551. https:// pubmed.ncbi.nlm.nih.gov/16375657/11
Singh, B., Kaur, P., Gopichand, Singh, R. D., & Ahuja, P. S. (2008). Biology and chemistry of ginkgo biloba. Fitoterapia, 79(6), 401–18. https://doi.org/10.1016/j.fitote.2008.05.007
Tomino, C., Ilari, S., Solfrizzi, V., Malafoglia, V., Zilio, G., Russo, P., Proietti, S., Marcolongo, F., Scapagnini, G., Muscoli, C., & Rossini, P. M. (2021). Mild cognitive impairment and mild dementia: the role of ginkgo biloba (egb 761®). Pharmaceuticals (Basel, Switzerland), 14(4). https://doi.org/10.3390/ph14040305
Vellas, B., Coley, N., Ousset, P. J., Berrut, G., Dartigues, J. F., Dubois, B., … & GuidAge Study Group. (2012). Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. The Lancet Neurology, 11(10), 851-859. https://www.proquest.com/docview/1082805442?accountid=176901
Welcome, M. O. (2019). Gut microbiota disorder, gut epithelial and blood-brain barrier dysfunctions in etiopathogenesis of dementia: molecular mechanisms and signaling pathways. Neuromolecular Medicine, 21(3), 205–226. https://doi.org/10.1007/ s12017-019-08547-512
Wolters, F. J., & Ikram, M. A. (2018). Epidemiology of dementia: the burden on society, the challenges for research. In Biomarkers for Alzheimer’s Disease Drug Development. Humana Press, New York, NY. https://pubmed.ncbi.nlm.nih.gov/29512062/
Yancheva, S., Ihl, R., Nikolova, G., Panayotov, P., Schlaefke, S., & Hoerr, R. (2009). Ginkgo biloba extract egb 761, donepezil or both combined in the treatment of alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging & Mental Health, 13(2), 183–190. https://web-p-ebscohost- com.torrens.idm.oclc.org/ehost/pdfviewer/pdfviewer?vid=1&sid=1c882ef4- f32c-448a-9070-7a8fb25ddd29%40redis
Zhang, H., Cao, Y., Pei, H., Wang, H., Ma, L., Wang, Z., … & Li, H. (2020). Shenmayizhi formula combined with ginkgo extract tablets for the treatment of vascular dementia: a randomized, double-blind, controlled trial. Evidence-Based Complementary and Alternative Medicine, 2020. https://doi.org/10.1155/2020/8312347
